Tenofovir alafenamide use in pregnant and lactating women living with HIV

References

• Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Transmission in the United States. [ cited 2019 Oct 11]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf
   Google Scholar
• Eke AC, McCormack SA, Best BM, et al. Pharmacokinetics of increased nelfinavir plasma concentrations in women during pregnancy and postpartum. J Clin Pharmacol. 2019;59(3):386–393.
   Google Scholar
• Teasdale CA, Marais BJAbrams EJ., Hiv: prevention of mother-to-child transmission. Bmj Clin Evid. 2011 Jan;17(2011):0909.
   Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–1180.
   Google Scholar
• Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. The World Health Organization (WHO). [ cited 2019 Oct 11]. Available from: https://www.who.int/hiv/pub/mtct/guidelines/en/
   Google Scholar
• European AIDS Clinical Society (EACS) Guidelines. [ cited 2019 Oct 11]. Available from: https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• Panel on treatment of pregnant women with HIV infection and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in transmission in the United States. 2018 [cited 2019 Nov 1]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf
   Google Scholar
• Fowler MG, Qin M, Fiscus SA, et al., Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726–1737.
   Google Scholar
• Nachega JB, Uthman OA, Mofenson LM, et al. Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2017;76(1):1–12.
   Google Scholar
• Pintye J, Baeten JM, Celum C, et al. Maternal tenofovir disoproxil fumarate use during pregnancy is not associated with adverse perinatal outcomes among HIV-infected East African women: a prospective study. J Infect Dis. 2017;216(12):1561–1568.
   Google Scholar
• Hill A, Hughes SL, Gotham D, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018;4(2):72–79.
   Google Scholar
• De Clercq E. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochem Pharmacol. 2018;153:2–11.
   Google Scholar
• De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1–7.
   Google Scholar
• Podany AT, Bares SH, Havens J, et al., Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. AIDS. 2018;32(6):761–765.
   Google Scholar
• Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016;125:63–70.
   Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–455.
   Google Scholar
• Baxi SM, Scherzer R, Greenblatt RM, et al. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS. 2016;30(4):609–618.
   Google Scholar
• Lavra ZMM, de Medeiros FPM, da Silva RMF, et al. Formulation, development and scale-up of fixed-dose combination tablets containing zidovudine, lamivudine and nevirapine. Curr HIV Res. 2019. DOI:10.2174/1570162X17666190927162155
   Google Scholar
• Janelle JW, Kariyawasam V. Single-tablet combination therapy for HIV infection in pregnancy. Clin Obstet Gynecol. 2019;62(4):804–815.
   Google Scholar
• Eke AC, Stek AM, Wang J, et al. Darunavir pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2020;83(4):373–380.
   Google Scholar
• Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5(5):352–359.
   Google Scholar
• Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected pregnant women. J Acquir Immune Defic Syndr. 2016;72(3):289–296.
   Google Scholar
• Eke AC, Chakhtoura N, Kashuba A, et al. Rilpivirine plasma and cervicovaginal concentrations in women during pregnancy and postpartum. J Acquir Immune Defic Syndr. 2018;78(3):308–313.
   Google Scholar
• Ye ZW, Augustijns P, Annaert P. Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. Drug Metab Dispos. 2008;36(7):1315–1321.
   Google Scholar
• Tam VH, Kabbara S, Yeh RF, et al. Impact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob Agents Chemother. 2006;50(11):3950–3952.
   Google Scholar
• Kang D, Schwartz JB, Verotta D. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models. Stat Med. 2004;23(16):2551–2566.
   Google Scholar
• Boyd SD, Sampson MR, Viswanathan P, et al. Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint. AIDS. 2019;33(6):1089–1093.
   Google Scholar
• Eke AC, Mirochnick MH. Cobicistat as a pharmacoenhancer in pregnancy and postpartum: progress to date and next steps. J Clin Pharmacol. 2019;59(6):779–783.
   Google Scholar
• Eke AC, Mirochnick M. Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women. Expert Opin Drug Metab Toxicol. 2019;15(7):523–525.
   Google Scholar
• Momper JD, Best BM, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018;32(17):2507–2516.
   Google Scholar
• Schalkwijk S, Colbers A, Konopnicki D, et al. First reported use of elvitegravir and cobicistat during pregnancy. AIDS. 2016;30(5):807–808.
   Google Scholar
• De Clercq E. The acyclic nucleoside phosphonates (ANPs): Antonin Holy’s legacy. Med Res Rev. 2013;33(6):1278–1303.
   Google Scholar
• Aloy B, Tazi I, Bagnis CI, et al. Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys? AIDS Rev. 2016;18(4):184–192.
   Google Scholar
• Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49(5):1898–1906.
   Google Scholar
• Ogawa E, Furusyo N, Nguyen MH. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:3197–3204.
   Google Scholar
• Birkus G, Bam RA, Willkom M, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2016;60(1):316–322.
   Google Scholar
• Birkus G, Wang R, Liu X, et al. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother. 2007;51(2):543–550.
   Google Scholar
• Birkus G, Hajek M, Kramata P, et al. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*. Antimicrob Agents Chemother. 2002;46(5):1610–1613.
   Google Scholar
• Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs. 2018;78(17):1817–1828.
   Google Scholar
• Markowitz M, Zolopa A, Squires K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014;69(5):1362–1369.
   Google Scholar
• Begley R, Das M, Zhong L, et al. Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals. J Acquir Immune Defic Syndr. 2018;78(4):465–472.
   Google Scholar
• Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015;59(6):3563–3569.
   Google Scholar
• Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29(2):384–390.
   Google Scholar
• Seifert SM, Chen X, Meditz AL, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses. 2016;32(10–11):981–991.
   Google Scholar
• Custodio JGW, Callebaut C. The pharmacokinetics of tenofovir and tenofovir diphosphate following administration of tenofovir alafenamide versus tenofovir disoproxil fumarate (Abstract 6). Paper presented at: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; 2015; Washington DC.
   Google Scholar
• Atta MG, De Seigneux S, Lucas GM. Clinical Pharmacology in HIV Therapy. Clin J Am Soc Nephrol. 2019;14(3):435–444.
   Google Scholar
• Genvoya® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets for oral use. [ cited 2019 Oct 8]. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf
   Google Scholar
• Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018;32(11):1431–1442.
   Google Scholar
• Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3(4):e158–165.
   Google Scholar
• Mills A, Crofoot G Jr., McDonald C, et al. tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439–445.
   Google Scholar
• Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017;4(5):e195–e204.
   Google Scholar
• Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455–1465.
   Google Scholar
• Wang H, Lu X, Yang X, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016;95(41):e5146.
   Google Scholar
• Callebaut C, Stepan G, Tian Y, et al. In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2015;59(10):5909–5916.
   Google Scholar
• Spinner C, Brunetta J, Shalit P, et al. DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF. 10th IAS Conference on HIV Science (IAS 2019); 2019 Jul 21–24; Mexico City. Abstract TUAC0403LB.
   Google Scholar
• Margot NA, Liu Y, Miller MD, et al. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. Antiviral Res. 2016;132:50–58.
   Google Scholar
• Everson GT. Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am. 1992;21(4):751–776.
   Google Scholar
• Sheffield JS, Siegel D, Mirochnick M, et al. Designing drug trials: considerations for pregnant women. Clin Infect Dis. 2014;59(Suppl 7):S437–444.
   Google Scholar
• Wang H, Yan Z, Dong M, et al. Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy. Arch Gynecol Obstet. 2012;285(6):1535–1540.
   Google Scholar
• Beigi RH, Han K, Venkataramanan R, et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol. 2011;204(6 Suppl 1):S84–88.
   Google Scholar
• Kurzatkowski W, Ostrowska H, Doroszko M. Serum cathepsin A activity in pregnant, parturient and puerperal patients. Zentralblatt fur Gynakologie. 1990;112(4):227–229.
   Google Scholar
• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595–612.
   Google Scholar
• Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20(4–7):641–648.
   Google Scholar
• Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71(2):619–627.
   Google Scholar
• Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19(7):687–692.
   Google Scholar
• Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol. 2005;289(4):R963–969.
   Google Scholar
• Momper JD, Best B, Wang J, et al. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. 22nd International AIDS Conference; 2018 Jul 23–27; Amsterdam, The Netherlands.
   Google Scholar
• Brooks K, Pinilla M, Shapiro D, et al. Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum. Oral abstract presented at 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs; 2019 May 14–16; Noordwijk, The Netherlands.
   Google Scholar
• Evaluating the efficacy and safety of dolutegravir-containing versus efavirenz-containing antiretroviral therapy regimens in HIV-1-Infected Pregnant Women and Their Infants (VESTED). Clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). Available from: https://clinicaltrials.gov/ct2/show/NCT03048422.
   Google Scholar
• Tseng A, Hughes CA, Wu J, et al. Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences. Ann Pharmacother. 2017;51(11):1008–1022.
   Google Scholar
• Pyra M, Anderson PL, Hendrix CW, et al. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. AIDS. 2018;32(13):1891–1898.
   Google Scholar
• IMPAACT. 2009. Evaluating the pharmacokinetics, feasibility, acceptability, and safety of oral pre-exposure prophylaxis for HIV prevention during pregnancy and postpartum (IMPAACT 2009). [cited 2020 Feb 12] Available from: https://clinicaltrials.gov/ct2/show/NCT03386578
   Google Scholar
• Aizire J, Brooks KM, Mirochnick M, et al. Antenatal intracellular concentrations of tenofovir diphosphate and emtricitabine triphosphate and associations between tenofovir diphosphate and severe adverse pregnancy outcomes: IMPAACT-PROMISE (1077BF) trial. J Acquir Immune Defic Syndr. 2020;83(2):173–180.
   Google Scholar
• Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV/AIDS Rep. 2018;15(1):49–59.
   Google Scholar
• Hare CB, Coll J, Ruane P, et al. The Phase 3 DISCOVER Study: Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 2019; Seattle, WA, USA.
   Google Scholar
• Yager J, Brooks K, Castillo-Mancilla J, et al. Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy. 20th International Workshop on Clinical Pharmacology of HIV Hepatitis & Other Antiviral Drugs; 2019 May 14–16; Noordwijk, The Netherlands.
   Google Scholar
• Ting SL, Zack J, Yan M et al. Enhanced Exposure of Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMC) by Tenofovir Alafenamide (TAF) Compared with Tenofovir Disoproxil Fumarate (TDF). American Society of Microbiology (ASM) Microbe Conference; 2016 June 16–20; Boston, Massachussetts.
   Google Scholar
• Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Research Part B, Dev Reprod Toxicol. 2007;80(1):18–27.
   Google Scholar
• Gilbert-Barness E. Teratogenic causes of malformations. Ann Clin Lab Sci. 2010;40(2):99–114.
   Google Scholar
• Eke AC, Dooley KE, Sheffield J. Pharmacologic research in pregnant women – time to get it right. N Engl J Med. 2019;380(14):1293–1295.
   Google Scholar
• Zash RM, Williams PL, Sibiude J, et al. Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges. Expert Opin Drug Saf. 2016;15(11):1501–1513.
   Google Scholar
• James JS. HIV & AIDS treatment registry database: public registry now online. AIDS Treat News. 1999;326:3.
   Google Scholar
• Tenofovir Alafenamide (TAF). [ cited 2019 Oct 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208464Orig1s000TOC.cfm
   Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815.
   Google Scholar
• Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Erad. 2019;5(1):41–43.
   Google Scholar
• Orkin C, Eron J, Rockstroh J, et al. Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in antiretroviral treatment (ART)-naïve, HIV-1-infected adults: AMBER Week 96 results. HIV Glasgow; 2018; Glasgow, Scotland.
   Google Scholar
• McCann K, Moorhouse M, Sokhela S, et al. The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC +DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV. 17th European AIDS Conference; 2019; Basel, Switzerland.
   Google Scholar
• Greene SA, Chen J, Prince HMA, et al. Population modeling highlights drug disposition differences between tenofovir alafenamide and tenofovir disoproxil fumarate in the blood and semen. Clin Pharmacol Ther. 2019;106(4):821–830.
   Google Scholar
• Ackaert O, McDougall D, Perez Ruixo C, H C. Population pharmacokinetic analysis for darunavir and tenofovir alafenamide in HIV-1-infected patients on the darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (AMBER and EMERALD studies). 19th International Workshop on Clinical Pharmacology of Antiviral Therapy; 2018; Baltimore, Maryland,USA.
   Google Scholar
• Ke AB, Rostami-Hodjegan A, Zhao P, et al. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol. 2014;54:53–69.
   Google Scholar
• Shoji K, Best B, Mirochnick M, et al. Population pharmacokinetic assessment of factors associated with tenofovir clearance in pregnant and postpartum women with HIV infection in IMPAACT P1026s. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2015; San Diego, California, USA.
   Google Scholar
• Joshi AA, Vaidya SS, St-Pierre MV, et al. Placental ABC transporters: biological impact and pharmaceutical significance. Pharm Res. 2016;33(12):2847–2878.
   Google Scholar
• Ke AB, Greupink R, Abduljalil K. Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations. CPT Pharmacometrics Syst Pharmacol. 2018;7(2):103–110.
   Google Scholar
• Castillo-Mancilla JR. Adherence to ART and PrEP: tARGETing the Ideal Measure. Clin Infect Dis. 2019. DOI:10.1093/cid/ciz651
   Google Scholar
• Brooks KM, Anderson PL. Pharmacologic-based methods of adherence assessment in HIV prevention. Clin Pharmacol Ther. 2018;104(6):1056–1059.
   Google Scholar
• Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1):e0170-17.
   Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599.
   Google Scholar
• Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–829.
   Google Scholar
• Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.
   Google Scholar
• Seifert SM, Castillo-Mancilla JR, Erlandson K, et al. Brief report: adherence biomarker measurements in older and younger hiv-infected adults receiving tenofovir-based therapy. J Acquir Immune Defic Syndr. 2018;77(3):295–298.
   Google Scholar
• Castillo-Mancilla JR, Searls K, Caraway P, et al. Short communication: tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses. 2015;31(4):428–432.
   Google Scholar
• Castillo-Mancilla JR, Morrow M, Coyle RP, et al. Tenofovir diphosphate in dried blood spots is strongly associated with viral suppression in individuals with human immunodeficiency virus infections. Clin Infect Dis. 2019;68(8):1335–1342.
   Google Scholar
• Yager JL, Coyle RP, Coleman SS, et al. Moderately high tenofovir diphosphate in dried blood spots indicates drug resistance in viremic persons Living with HIV. J Int Assoc Provid AIDS Care. 2019;18:2325958219888457.
   Google Scholar